紫龙金治疗非小细胞肺癌的系统评价  

Zilongjin for NSCLC: A Systematic Review

作　　者：刘春香[1] 王辉[1] 翟静波[1] 邢冬梅[1] 雷翔[1] 任明[1] 高洪才[1] 

机构地区：[1]天津中医药大学,天津300193

出　　处：《辽宁中医杂志》2013年第12期2448-2453,I0017,共7页Liaoning Journal of Traditional Chinese Medicine

基　　金：教育部新世纪优秀人才计划(NCET-09-0900)

摘　　要：目的:系统评价紫龙金治疗非小细胞肺癌的疗效和安全性。方法:通过检索SinoMed数据库、维普、万方、CNKI数据库、PubMed、Cochrane图书馆临床对照试验数据库,并手工检索肿瘤学相关期刊等,按照纳入排除标准选择文献,提取资料,采用RevMan5.1软件进行质量评价和Meta分析。结果:共纳入6个研究,合计346例患者。纳入文献的质量普遍偏低。Meta分析结果提示,紫龙金配合化疗与对照组比较,能提高肿瘤疗效[RR=2.51,95%CI(1.22,5.13),P=0.01]、提高生存质量[RR=12.72,95%CI(4.70,34.43),P<0.01]和[RR=2.67,95%CI(1.11,6.43),P=0.03]、改善中医证候[RR=14.56,95%CI(5.50,38.55),P<0.01]、提高NK细胞活性[WMD=9.78,95%CI(6.86,12.70),P<0.01]和IL-2水平[WMD=3.75,95%CI(0.55,6.95),P=0.02]。紫龙金可减轻化疗引起恶心呕吐、腹泻、皮疹等不良反应,未发现明显毒副作用。结论:紫龙金辅助化疗治疗非小细胞肺癌具有增效减毒作用,因纳入研究质量尚低,还需开展高质量临床试验证实紫龙金治疗肺癌的有效性和安全性,而中医药维持治疗肿瘤显示出良好的效果,亦为紫龙金临床研究指明方向。Objective ：To evaluate the clinical efficacy and safety of Zilongjin for NSCLC. Methods：All randomized controlled trials of Zilongjin for NSCLC were searched from database （ sinoMed, VIP, Wangfang, CNKI, pubmed, The Coehrane library） and other oneology journals. According to the inclusive and exclusive criteria, the literature was selected for extracting the data. The quality evaluation and Meta analyses were conducted by using Revman 5.1 sofeware. Results ： Six RCTs involving 346 patients were included. The quality of the trials was generally low. The results of Meta analyses showed that the treatment group of Zilongjin combined with chemotherapy compared with the control group could increase tumor efficacy [ RR = 2.51,95 % CI （ 1.22, 5.13 ）, P = 0.011, improve the quality of life [ RR = 12.72,95 % CI （ 4.70,34.43 ）, P 〈 0.01 ] and [ RR = 2.67,95 % CI （ 1.11, 6.43 ）, P = 0.03 ], improve TCM syndromes [ RR = 14.56,95 % CI （ 5.50,38.55 ）, P 〈 0. 01 ], increase NK cell activity [ WMD = 9.78,95 % CI （ 6.86,12.70 ）, P 〈 0. 01 ] and the level of IL 2 [ WMD = 3.75,95 % CI （ 0.55,6.95 ）, P = 0.02 ]. Zilongjin com bined with chemotherapy could relieve chemotherapy induced nausea and vomiting, diarrhea, skin rashes and other adverse reac tions, and there were no obvious side effects. Conclusion：Zilon^in combined with chemotherapy for NSCLC had synergy and atten uation effect. As the quality of included studies were still low, there was necessary to conduct high quality clinical trials to con firm the efficacy and safety of treatment of Zilongjin for lung cancer. Besides, TCM showed good effect in maintenance treatment of tumors and also indicated the direction of Zilonziin clinical studies.

关 键 词：紫龙金 肺癌 系统评价 

分 类 号：R734.2[医药卫生—肿瘤]